Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · IEX Real-Time Price · USD
1.610
+0.010 (0.63%)
At close: Jul 26, 2024, 3:57 PM
1.590
-0.020 (-1.24%)
After-hours: Jul 26, 2024, 7:38 PM EDT
Alterity Therapeutics Revenue
Alterity Therapeutics had revenue of 1.90M AUD in the half year ending December 31, 2023, a decrease of -19.43%. This brings the company's revenue in the last twelve months to 3.43M, down -33.38% year-over-year. In the fiscal year ending June 30, 2023, Alterity Therapeutics had annual revenue of 3.92M, down -23.56%.
Revenue (ttm)
3.43M AUD
Revenue Growth
-33.38%
P/S Ratio
n/a
Revenue / Employee
311,929 AUD
Employees
11
Market Cap
14.28M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Flora Growth | 74.78M |
Star Equity Holdings | 42.56M |
Kiora Pharmaceuticals | 16.00M |
BIMI International Medical | 5.85M |
Immuron | 2.43M |
Sol-Gel Technologies | 1.72M |
Lumos Pharma | 1.53M |
QT Imaging Holdings | 1.40M |
ATHE News
- 3 days ago - Alterity Therapeutics to Present at MST Financial Webinar - GlobeNewsWire
- 10 days ago - Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy - GlobeNewsWire
- 10 days ago - Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar - GlobeNewsWire
- 2 months ago - Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review - GlobeNewsWire
- 3 months ago - Appendix 4C – Q3 FY24 Quarterly Cash Flow Report - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia - GlobeNewsWire